Imaging Retinal Vasculature in Infant Eyes

Description

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

Conditions

Retinopathy of Prematurity

Study Overview

Study Details

Study overview

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

Elucidating Perifoveal Vasculature Development in Infants

Imaging Retinal Vasculature in Infant Eyes

Condition
Retinopathy of Prematurity
Intervention / Treatment

-

Contacts and Locations

Durham

Duke University, Durham, North Carolina, United States, 27710

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
  • * Parent/Legal Guardian is able and willing to consent to study participation for the infant
  • * Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit
  • * Participant or Parent/Legal Guardian unwilling or unable to provide consent
  • * Infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
  • * Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)

Ages Eligible for Study

to 2 Months

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Duke University,

Xi Chen, MD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

2027-08-31